

Esophageal Oncology group : Treatment map Jul.2023.

UICC 8th	Standard treatment in Japan		Trials ongoing or follow up	
Stage I (N0)	Endoscopic resection (ESD/EMR) + CRT		<p>JCOG1904 CRT: IFI⁵⁾ vs. ENI⁶⁾ 2020/03~ Ongoing</p> <p>JCOG2013 (±NeoCF²⁾/DCF³⁾ Esophagectomy:</p>	
Stage I (N1)	Esophagectomy ¹⁾	Concurrent CRT (CF-RT ⁴⁾)	<p>Upper and Middle thoracic Esophageal Squamous Cell Cancer</p> <p>JCOG1804E Neo CF²⁾/DCF³⁾/FLOT⁷⁾ +Nivolumab +Esophagectomy</p> <p>2019/3~ Ongoing</p> <p>JCOG2206 NeoCF²⁾/DCF³⁾ +Esophagectomy:</p> <p>Surgery alone vs Nivolumab vs S-1</p> <p>2023/7~ Ongoing</p>	
Stage II	Neoadjuvant chemotherapy (Neo DCF ³⁾) + Esophagectomy ¹⁾	Adjuvant Nivolumab (Neo CRT + Esophagectomy)	Concurrent CRT (CF-RT ⁴⁾) (+Salvage esophagectomy or endoscopic resection)	<p>SCLN⁸⁾ Dissection vs Preservation</p> <p>2022/8~ Ongoing</p>
Stage III			<p>JCOG2203 Adenocarcinoma of EGJ⁹⁾ Esophagectomy:</p> <p>Upfront surgery vs Neo DOS¹⁰⁾/FLOT⁷⁾ 2023/7~ Ongoing</p>	
T4a/M1LYM Resectable	Neoadjuvant chemotherapy + Esophagectomy	Concurrent CRT	<p>JCOG1510 Concurrent CRT vs. Induction DCF³⁾ + Concurrent CRT or Esophagectomy 2018/2~ Follow up period</p>	
T4b/M1LYM Unresectable	Concurrent CRT			
Stage IVB	1 st line chemotherapy: CF ²⁾ + Pembrolizumab	2 nd line chemotherapy: Paclitaxel	<p>JCOG1314 (1st line) CF²⁾ vs. biweekly DCF³⁾</p> <p>2014/9~ Follow up period</p>	
Recurrent	CF ²⁾ + Nivolumab	Docetaxel		
	Nivolumab + Ipilimumab	If no previous ICIs ¹²⁾ : Nivolumab		
		Pembrolizumab (CPS ≥10)		

1) Thoracoscopic or open esophagectomy with 2-3 field lymph node dissection 2) CF, CDDP + 5-FU 3) DCF, DOC + CDDP + 5-FU 4) CF-RT, CDDP + 5-FU + radiation therapy 5) IFI, Involved field irradiation 6) ENI, Elective lymph node irradiation 7) FLOT, 5-FU + LV + L-OHP + DOC 8) SCLN, Supraclavicular lymph node 9) EGJ, Esophagogastric junction 10) DOS, DOC + L-OHP + S-1 11) ICI, Immune checkpoint inhibitor